PERSPECTIVES

Menopause as a potential cause for higher prevalence of low back pain in women than in age-matched men

Yi Xiang J. Wang*

Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong Special Administrative Region

Received 26 December 2015; received in revised form 16 May 2016; accepted 27 May 2016
Available online 14 June 2016

KEYWORDS
epidemiology; intervertebral disc degeneration; low back pain; oestrogen; physiological sex difference

Summary Female sex hormones play an important role in the aetiology and pathophysiology of a variety of musculoskeletal degenerative diseases. Postmenopausal women show accelerated disc degeneration due to relative oestrogen deficiency, resulting in narrower intervertebral disc space in women than age-matched men, increased prevalence of spondylolisthesis, and increased prevalence of facet joint osteoarthritis. Postmenopausal women also show higher osteoporosis related spine fracture rate, particularly at the thoracic–lumbar junction site. I propose the concept that low back pain (LBP) is more prevalent in postmenopausal women than age-matched men and is associated with the physiological changes caused by the relatively lower level of sex hormones after menopause in women. Considering hormone replacement treatment (HRT)’s consistent efficacy reported with menopause-associated osteoarthritis, an in-depth understanding of the role of the gonadal hormones in LBP modulation warrants further study. HRT initiated at early postmenopausal phase may be protective for recurring LBP. If this is the case, further cost–benefit analysis should be performed for optimal HRT regimen in cases of women with high risk of recurring severe LBP.

© 2016 The Author(s). Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Oestrogens participate in a variety of biological processes through different molecular mechanisms. Oestrogen has favourable effects on the lipid profile, antioxidant activity, and enhanced fibrinolysis [1]. Female sex hormones also play an important role in the aetiology and pathophysiology of a variety of musculoskeletal degenerative diseases. The

* Corresponding author. Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong Special Administrative Region.
E-mail address: yixiang_wang@cuhk.edu.hk.

http://dx.doi.org/10.1016/j.jot.2016.05.012
2214-031X/© 2016 The Author(s). Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
prevalence of osteoarthritis (OA) is higher among women than among men, and this prevalence increases considerably after menopause [2,3]. Moreover, with the same degree of radiographic damage, OA is also more symptomatic in women [2,3]. Young men are more susceptible to disc degeneration than young women, probably due to increased mechanical stress and physical injury [4–6]. However, recent evidence suggests that disc degeneration is common or more severe in elderly women than in elderly men [7,8]. Postmenopausal women show accelerated disc degeneration due to relative oestrogen deficiency [9,10]. Postmenopausal women also show narrower intervertebral disc space than age-matched men [8,11], increased prevalence of spondylolisthesis [12–14], and increased prevalence of facet joint arthritis [15].

In the literature, the reported population-based low back pain (LBP) prevalence varies as it depends on the definitions of LBP as well as the survey method. A number of reports suggest that women have higher prevalence of LBP than men [16–19], despite the fact that young and middle-aged men have higher prevalence and more severe intervertebral disc degeneration [4–6]. The higher LBP prevalence in women is probably due to many factors, including heightened pain sensitivity among women [20,21], menstrual cycle fluctuations, biologic response and stress to pregnancy and childbearing, and perimenopausal abdominal weight gain [19]. Recently, it has been shown that genetics also plays a role in the development of LBP [1,22,23]. A very recent systematic review, which was limited to population based studies with the same LBP criteria applied to both men and women in the same community, demonstrates, compared with middle-aged individuals, a further increased LBP prevalence in women than in men was noted after menopause age [24]. By contrast, in an evaluation of pain characteristics of adults aged ≥ 65 years referred to a tertiary pain care clinic, the older patients had relatively more physical problems concordant with their complaints, but fewer psychological factors contributing to disability than the younger patients [25,26].

In some studies, LBP is strikingly more prevalent in postmenopausal women than age-matched men. In 1969, Lawrence [27] surveyed 713 men and 809 women aged ≥ 35 years with lumbar radiography in Manchester, UK. Back—hip–sciatic pain was present at the time of the survey in 79 (11%) of the men and in 153 (19%) of the women. In those with pain at the time of the survey, the incidence had risen up to age 40 years in men and then remained constant, but in women it continued to rise sharply up to and over the age of 65 years (Figure S1A). In 1995, Papageorgiou et al [28] reported the South Manchester Back Pain Survey with a study population of 4501 (age 18–75 years). The 1-month period prevalence of LBP was 31.2%, 33.1%, 38.5%, and 34.9% for the age ranges of 18–29 years, 30–44 years, 45–59 years, and ≥ 60 years, respectively, for men; 32.2%, 41.5%, 49.2%, and 43.7% for the age ranges of 18–29 years, 30–44 years, 45–59 years, and ≥ 60 years, respectively, for women. In 2010, Cho et al [29] published LBP data collected for 4181 individuals from a rural farming community in Korea. The participants had a mean age of 56.6 years and 55.5% were women. Six-month prevalence of LBP was 38.5% for men and 55.6 for women. The prevalence of LBP increased significantly with age in women (Figure S1B). Data from the Osteoporotic Fractures in Men (Hong Kong) and Osteoporotic Fractures in Women (Hong Kong) Studies were published in 2013 [8]; 2000 Chinese men and 2000 Chinese women, aged ≥ 65 years, were prospectively recruited from local communities for a prospective cohort study from August 2001 to March 2003. The LBP prevalence was 30.6% for men and 53.3% for women (p < 0.001). While postmenopausal women also show higher osteoporosis-related spine fracture rate compared with age-matched men, and vertebral fracture is a known cause of back pain and related disability [30], the accelerated spine degeneration caused by the relatively lower level of sex hormones after menopause in women [9,10], including narrower intervertebral disc space, higher lumbar spondylolisthesis prevalence, and increased prevalence of facet joint osteoarthritis, may be an additional source of LBP in elderly women.

Oestrogen with or without a progestogen prevents early postmenopausal bone loss and augments bone mass in late postmenopause as effectively as the bisphosphonates [29]. Hormone replacement treatment (HRT) has consistently been shown to be protective against menopause-associated OA [31–35].

However, to date the clinical data on HRT’s effects on LBP remain contradictory. For example, Baron et al [36] found that women on HRT maintained intervertebral disc height compared with untreated postmenopausal women. They suggested that the oestrogenic milieu may be relevant because of the significant impact it has on the hydrophilic glycosaminoglycans, the water content, collagen, and elastin of the intervertebral discs. The maintenance of adequate disc height may allow the intervertebral discs to retain their discoid shape and viscoelastic function, containing vertical forces which may threaten spinal architecture leading to vertebral body compression fractures [36]. Kylönen et al’s [37] longitudinal clinical study supports that oestrogen–progestin replacement therapy was beneficial for lumbar spine mobility. In an experimental study, Li et al [38] reported that resveratrol, a phytoestrogen, is a potent anabolic mediator of bovine intervertebral disc cartilage homeostasis to slow the progression of disc degeneration. However, in one study Musgrave et al [39] reported that women taking HRT had more back pain and back pain-related disability than did those not taking HRT. In another study Symmons et al [40] also reported that oestrogen use was more common in the group reporting back pain than in the group without back pain. Considering that HRT is known to decrease vertebral fracture rate [31], and protect intervertebral disc [36], and maybe also facet joint [12], Musgrave et al’s [39] and Symmons et al’s [40] findings look counterintuitive. In one systemic review, Bressler et al [25] noted that there is an under-representation of the older population in the LBP pain literature. They stressed the need for future studies to improve the reporting of age information to make prevalence studies more informative and applicable.

The expert views of HRT have evolved during the past 10 years since the publication of Women’s Health Initiative trials [41,42]. Since the initial publication of the Women’s Health Initiative hormone trial results, multiple secondary analyses have yielded interesting data that suggested that
the risk of coronary heart disease was dependent upon both the timing of initiating hormone exposure as well as the age of the woman at the time of HRT initiation [43, 44]. Specifically, in the oestrogen-alone trial, a nonstatistically significant reduction in coronary heart disease risk was noted in participants aged 50–59 years [44]. Dose regimen, combination of oestrogen with progestins versus oestrogen alone, the administration route, and duration of treatment such as the choice of repetitive or periodic administration simulating the menstrual cycle are some of the factors that may be involved in benefit discrepancies. The Estrogen and Thromboembolism Risk study confirmed that oral oestrogens increased venous thromboembolism risk, whereas transdermal oestrogens had little or no impact on the development of thrombosis [45]. Recent Korean data do not support HRT history for the risk of breast cancer in women [46]. The presence of gene polymorphisms may also be implicated. HRT may benefit a large number of postmenopausal women, but a subset of women may have higher risk of cardiovascular and thrombotic complications [47]. Oestrogen receptor modulators and phytostrogens may retain the desired effects but avoid undesirable effects [48]. Considering HRT’s efficacy reported with menopause-associated OA in many studies, an in-depth understanding of the role of the gonadal hormones in LBP may retain the desired effects but avoid undesirable effects. HRT initiated at early menopausal phase may be protective for recurring LBP, as LBP tends to be a recurring phenomenon in nature. HRT protects both bone [31] and disc tissue [12, 36]. If this is the case, further cost–benefit analysis should be performed for optimal HRT regimen in cases of women with high risk of recurring severe LBP.

Conflicts of interest
The author has no conflicts of interest to declare.

Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jot.2016.05.012.

References
[1] Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogens on the vascular system. Braz J Med Biol Res 2003;36:1143–58.
[2] Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005;13:769–81.
[3] Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778–99.
[4] Miller JA, Schmatz C, Schultz AB. Lumbar disc degeneration: correlation with age, sex, and spine level in 600 autopsy specimens. Spine 1988;13:173–8.
[5] Lebkowski WJ. Autopsy evaluation of the extent of degeneration of the lumbar intervertebral discs. Pol Merkuriusz Lek 2002;13:188–90 [in Polish].
[6] Takatalo J, Karppinen J, Niinimäki J, Taimela S, Nâyhá S, Järvelin MR, et al. Prevalence of degenerative imaging findings in lumbar magnetic resonance imaging among young adults. Spine 2009;34:1716–21.
[7] Wang YX, Kwok AW, Griffith JF, Leung JC, Ma HT, Ahuja AT, et al. Relationship between gender, bone mineral density, and disc degeneration in the lumbar spine: a study in elderly subjects using an eight level MRI-based disc degeneration grading system. Osteoporos Int 2011;22:91–6.
[8] Wang YX, Griffith JF, Zeng XJ, Deng M, Kwok AW, Leung JC, et al. Prevalence and sex difference of lumbar disc space narrowing in elderly Chinese men and women: osteoporotic fractures in men (Hong Kong) and osteoporotic fractures in women (Hong Kong) studies. Arthritis Rheum 2013;65:1004–10.
[9] Wang YX, Griffith JF. Effect of menopause on lumbar disk degeneration: potential etiology. Radiology 2010;257:318–20.
[10] Wang YX, Wang QJ, Káplár Z. Postmenopausal Chinese women show accelerated lumbar disc degeneration compared with Chinese men. J Orthop Transl 2015;3:205–11.
[11] de Schepper EI, Damen J, van Meurs JB, Ginai AZ, Popham M, Hofman A, et al. The association between lumbar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. Spine 2010;35:531–6.
[12] He LC, Wang YX, Gong JS, Griffith JF, Zeng XJ, Kwok AW, et al. Prevalence and risk factors of lumbar spondylosis in elderly Chinese men and women. Eur Radiol 2014;24:441–8.
[13] Imada K, Matsui H, Tsuji H. Oophorectomy predisposes to degenerative spondylosis. J Bone Joint Surg Br 1995;77:126–30.
[14] DeVine JG, Schenk-Kisser JM, Skelly AC. Risk factors for degenerative spondylosis: a systematic review. Evid Based Spine Care J 2012;3:25–34.
[15] Kalichman L, Li L, Kim DH, Guermazi A, Berkin V, O’Donnell CJ, et al. Facet joint osteoarthritis and low back pain in the community–based population. Spine 2008;33:2560–5.
[16] Nagi SZ, Riley LE, Newby LG. A social epidemiology of back pain in a general population. J Chronic Dis 1973;26:769–79.
[17] Reisbord LS, Greenland S. Factors associated with self-reported back-pain prevalence: a population-based study. J Chronic Dis 1985;38:691–702.
[18] Calvo-Muñoz I, Gómez-Conesa A, Sánchez-Meca J. Prevalence of low back pain in children and adolescents: a meta-analysis. BMC Pediatr 2013;13:14.
[19] Bailey A. Risk factors for low back pain in women: still more questions to be answered. Menopause 2009;16:3–4.
[20] Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995;22:151–6.
[21] Rollman GB, Lautenbacher S. Sex differences in musculoskeletal pain. Clin J Pain 2001;17:20–4.
[22] Hestbaek L, Jachne IA, Leboeuf-Yde C, Kyvik KO, Manniche C. Heredity of low back pain in a young population: a classical twin study. Twin Res 2004;7:16–26.
[23] Pinheiro MB, Ferreira ML, Refshauge K, Colodro-Conde L, Carrillo E, Hopper JL, et al. Genetics and the environment affect the relationship between depression and low back pain: a co-twin control study of Spanish twins. Pain 2015;156:496–503.
[24] Wang YX, Wang QJ, Káplár Z. Increased low back pain prevalence in females than in males after menopause age: evidences based on synthetic literature review. Quant Imaging Med Surg 2016;6:199–206.
[25] Bressler HB, Keyes WJ, Rochon PA, Badley E. The prevalence of low back pain in the elderly. A systematic review of the literature. Spine 1999;24:1813–9.
[26] Mailis-Gagnon A, Nicholson K, Yegneswaran B, Zuwrowski M. Pain characteristics of adults 65 years of age and older referred to a tertiary care pain clinic. Pain Res Manag 2008;13:389–94.
[27] Lawrence JS. Disc degeneration. Its frequency and relationship to symptoms. Ann Rheum Dis 1969;28:121–38.
[28] Papageorgiou AC, Croft PR, Ferry S, Jayson MI, Silman AJ. Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine 1995;20:1889–94.
[29] Cho NH, Jung YO, Lim SH, Chung CK, Kim HA. The prevalence and risk factors of low back pain in rural community residents of Korea. Spine 2012;37:2001–10.
[30] Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793–800.
[31] Santen RJ, Allred DC, Ardon SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–66.
[32] Wluka AE, Davis SR, Bailey M, Stuckey SL, Cicuttini FM. Users of oestrogen replacement therapy have more knee cartilage than non-users. Ann Rheum Dis 2001;60:332–6.
[33] Ham KD, Loeher RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002;46:1956–64.
[34] Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum 2006;54:3194–204.
[35] Chlebowski RT, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, et al. Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause 2013;20:600–8.
[36] Baron YM, Brincat MP, Galea R, Calleja N. Intervertebral disc height in treated and untreated overweight post-menopausal women. Hum Reprod 2005;20:3566–70.
[37] Kyllönen ES, Heikkinen JE, Väinänen HK, Kurttila-Mateno E, Wilen-Rosenqvist G, Lankinen KS, et al. Influence of estrogen-progestin replacement therapy and exercise on lumbar spine mobility and low back symptoms in a healthy early post-menopausal female population: a 2-year randomized controlled trial. Eur Spine J 1998;7:381–6.
[38] Li X, Phillips FM, An HS, Ellman M, Thonar EJ, Wu W, et al. The action of resveratrol, a phytoestrogen found in grapes, on the intervertebral disc. Spine 2008;33:2586–95.
[39] Musergave DS, Vogt MT, Nevitt MC, Cauley JA. Back problems among postmenopausal women taking estrogen replacement therapy: the study of osteoporotic fractures. Spine 2001;26:1606–12.
[40] Symmons DPL, van Hemert AM, Vandenbergroucke JP, Valkenburg HA. A longitudinal study of back pain and radiological changes in the lumbar spines of middle aged women: I. Clinical findings. Ann Rheum Dis 1991;50:158–61.
[41] Ghazal S, Pal L. Perspective on hormone therapy 10 years after the WHI. Maturitas 2013;76:208–12.
[42] Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN, et al. Prevention of diseases after menopause. Climacteric 2014;17:540–56.
[43] Hsia J, Langer D, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and the risk of coronary heart disease. Arch Intern Med 2006;166:357–65.
[44] Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77.
[45] Scarcbin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–32.
[46] Bae JM, Kim EH. Hormone replacement therapy and risk of breast cancer in Korean women: a quantitative systematic review. J Prev Med Public Health 2015;48:225–30.
[47] Herrington DM, Klein KP. Invited review: pharmacogenetics of estrogen replacement therapy. J Appl Physiol (1985) 2001;91:2776–84.
[48] Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): a review of clinical data. Maturitas 2015;80:52–7.